Related Experiment Video
Updated: Sep 27, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
The Utility of Faecal Biomarkers in the Discrimination Between Acute Gastroenteritis and Inflammatory Bowel Disease
Maria Ling Lundström1, Christer Peterson2, David Amcoff1
1Gastroenterology Research Group, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.
Abstract:
Background: Acute infectious gastroenteritis (GE) and inflammatory bowel disease (IBD) may have similar clinical characteristics at onset, and discrimination between these two diagnoses can initially be challenging. Aim: To explore faecal biomarkers reflecting neutrophil, eosinophil, and epithelial activity to distinguish between acute GE and IBD onset. Methods: Faecal samples were collected from patients presenting with acute GE (n = 28), treatment-naïve patients with newly diagnosed IBD (n = 40), and healthy controls, HC (n = 40). Faecal biomarkers, including faecal calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN), were assessed by ELISA. The Kruskal-Wallis test was used for biomarker comparisons. To evaluate the discriminative capability of biomarkers, receiver operating characteristic (ROC) curves were established. Result: Patients with acute GE displayed elevated levels of all the tested biomarkers compared with HC (p < 0.001). Higher levels of faecal HNL (p < 0.001), EDN (p < 0.01), and MPO (p < 0.05) were seen in acute GE patients than in patients with newly diagnosed IBD. HNL yielded the highest discriminative capability between acute GE and IBD with AUC 0.74, 95%CI: 0.62-0.84. Conclusions: This exploratory study suggests that faecal biomarkers may provide complementary information in the differentiation of patients with suspected acute GE and new-onset IBD. Our findings indicate that faecal HNL may have the ability to distinguish between these conditions. However, given the exploratory design and limited sample size, findings should be interpreted with caution, and the discriminative value of HNL and the other biomarkers requires further validation in larger, well-characterised acute GE cohorts.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Serum Laboratory Studies, Stool Test, Breath Test
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Dysbiosis of the Gut Microbiota
